Sargramostim (rhu GM-CSF) Improves Survival of Non-Human Primates with Severe Bone Marrow Suppression after Acute, High-Dose, Whole-Body Irradiation.

Autor: Clayton NP; Global Rare Diseases, Sanofi Genzyme, Cambridge, Massachusetts., Khan-Malek RC; Global Biostatistics and Programming, Sanofi, Bridgewater, New Jersey., Dangler CA; Preclinical Safety, Sanofi, Framingham, Massachusetts., Zhang D; Global Biostatistics and Programming, Sanofi, Bridgewater, New Jersey., Ascah A; Liminal Biosciences, Laval, Canada., Gains M; Liminal Biosciences, Laval, Canada., Gardner B; Partner Therapeutics, Inc, Lexington, Massachusetts., Mockbee C; Partner Therapeutics, Inc, Lexington, Massachusetts., Keutzer JM; Global Rare Diseases, Sanofi Genzyme, Cambridge, Massachusetts., McManus J; Partner Therapeutics, Inc, Lexington, Massachusetts., Authier S; Charles River Laboratories, Laval, Canada.

Publikováno v: Radiation research [Radiat Res] 2021 Feb 01; Vol. 195 (2), pp. 191-199.